SRD5A1
SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
Overview
Catalyses the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms. Converts testosterone into 5-alpha-dihydrotestosterone (DHT), a more potent androgen as it is the preferred ligand for androgen receptor (AR) transactivation, making this reaction a key step in male sexual differentiation during development. Besides testosterone, it can also act on other steroids, including progesterone, androstenedione, and corticoids, producing metabolites with diverse roles.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.82, genetic association 0.03, clinical 0.96).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
- 1 · What it is
SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
- 2 · What goes wrong in cancer
Catalyses the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms.
- 3 · How drugs use it
No product in this corpus aims at SRD5A1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:11284 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P18405 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000145545 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: prostate cancer 0.60 (GraphQL API, CC0))
Biology
Catalyses the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms. Converts testosterone into 5-alpha-dihydrotestosterone (DHT), a more potent androgen as it is the preferred ligand for androgen receptor (AR) transactivation, making this reaction a key step in male sexual differentiation during development. Besides testosterone, it can also act on other steroids, including progesterone, androstenedione, and corticoids, producing metabolites with diverse roles. Hence, it plays a central role in sexual differentiation and androgen physiology. Location: Microsome membrane; Endoplasmic reticulum membrane (UniProt). Locus 5p15.31 (HGNC).
- Prostate cancer: Open Targets association 0.60 with prostate cancer (MONDO_0008315)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.96. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SRD5A1" OR ABSTRACT:"SRD5A1" OR TITLE:"steroid 5 alpha-reductase 1" OR ABSTRACT:"steroid 5 alpha-reductase 1" OR TITLE:"3-oxo-5-alpha-steroid 4-dehydrogenase 1" OR ABSTRACT:"3-oxo-5-alpha-steroid 4-dehydrogenase 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SRD5A1, not a curated reading list.